European Journal of Biomedical and Pharmaceutical Sciences

GENE THERAPY'S NEW ERA: FDA LEADERSHIP, INNOVATION, AND ACCESS IN RARE DISEASE TREATMENT

Nidhi Chauhan*, Patel Khadijah Harun Rasid*, Vaishali Patel, Rozinaparvin Patel, Zaheda Valid Gajerawala

ABSTRACT

Gene therapy, defined as the introduction of genetic material into a patient’s cells to treat or cure disease, has
entered a transformative phase, particularly for rare genetic disorders. Thousands of rare diseases affect millions of
individuals worldwide, most of which still lack effective treatment options. Gene- and cell-based therapies offer
the potential for long-term or curative outcomes by addressing underlying genetic defects. As of recent years,
multiple gene therapies have received regulatory approval, with many more under development. This review
explores the scientific principles of gene therapy, including viral vectors, gene editing technologies, and both ex
vivo and in vivo approaches. It also outlines the clinical development pathway from early research to clinical
application. Special emphasis is placed on regulatory advancements, including expedited approval pathways,
innovative designations, and evolving frameworks that support the development of therapies for rare diseases.
Additionally, the review discusses key challenges such as patient access, cost, long-term safety, and the need for
collaborative healthcare models. Overall, gene therapy represents a rapidly advancing field with significant
potential to transform the treatment landscape for rare diseases, while also presenting important scientific and
regulatory challenges.

Keywords: Gene therapy; Rare disease; Regulation; Drug development; Accelerated approval.